

CLAIMS

1. A vaccine composition comprising:
(a) a *Salmonella typhi* purified Vi polysaccharide and
5 (b) at least one other antigen
wherein the vaccine components are stable and do not interfere with each other.

10 2. A vaccine composition as claimed in claim 1 in which the other antigen is a hepatitis A antigen.

3. A vaccine composition according to claim 1 or claim 2 which additionally comprises an adjuvant.

15 4. A vaccine composition according to claim 3 wherein the adjuvant is a preferential stimulator of TH1-cell response.

5. A vaccine composition according to any preceding claim which additionally comprises a carrier.

20 6. A vaccine composition according to claim 4 in which the preferential stimulator of TH1-cell response is selected from the group of adjuvants comprising: 3D-MPL, 3D-MPL wherein the size of the particles of 3D-MPL is preferably about or less than 100nm, QS21, a mixture of QS21 and cholesterol, or a combination of two or more of said adjuvants.

25 7. A vaccine composition according to claim 6 in which the preferential stimulator of TH1-cell response is 3D-MPL.

8. A vaccine composition according to any one of claims 1 to 7 in which the
30 Hepatitis A antigen is derived from the HM-175 strain.

9. A vaccine composition according to any one of claims 1 to 8 in which an hepatitis B antigen is additionally present.

10. A vaccine composition as defined in claim 9 in which the Hepatitis B antigen is hepatitis surface antigen.

5 11. A vaccine composition according to claim 5 in which the carrier is selected from the group comprising aluminium hydroxide, aluminium phosphate and an oil in water emulsion.

10 12. A vaccine composition according to claim 11 in which the carrier is aluminium hydroxide.

13. A vaccine composition according to any one of claims 1 to 12 which additionally comprises a dengue antigen.

15 14. A vaccine composition according to claim 13 in which the dengue antigen is selected from the group comprising envelope (E) glycoprotein proteins, truncated envelope glycoprotein proteins and Dengue viral proteins.

20 15. A vaccine composition according to any one of claims 1 to 14 which additionally comprises an hepatitis E antigen.

16. A vaccine composition according to claim 15 in which the hepatitis E antigen is SAR 55.

25 17. A method of manufacture of Vi polysaccharide wherein the method comprises:
a. fermentation of a preculture of *S. typhi*;
b. extraction and purification of the Vi polysaccharide in the absence of phenol; and
c. vacuum drying and storage.

30 18. *S. typhi* Vi polysaccharide produced by the method of claim 17.

AI

Add claims
19-41